Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of OLC1 gene expression level in prognosis evaluation of bladder cancer

A gene expression level, bladder cancer technology, applied in the biological field, can solve the problems of including tumor-related molecular markers

Pending Publication Date: 2022-02-15
CHINA JAPAN FRIENDSHIP HOSPITAL +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The prognostic risk classification in the current diagnosis and treatment guidelines still relies on clinical characteristics such as recurrence history, tumor stage, grade, and tumor number, but tumor-related molecular markers have not yet been included

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of OLC1 gene expression level in prognosis evaluation of bladder cancer
  • Application of OLC1 gene expression level in prognosis evaluation of bladder cancer
  • Application of OLC1 gene expression level in prognosis evaluation of bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1. The application of the expression level of OLC1 gene in the prognosis assessment of bladder urothelial carcinoma

[0041] The expression level of OLC1 gene was detected in 70 tumor tissue samples from 70 bladder urothelial carcinoma cases and 38 bladder normal mucosa samples by real-time PCR method. Observe the correlation between OLC1 gene expression and patients' clinicopathological characteristics and recurrence, obtain independent factors affecting patients' recurrence-free survival, establish a recurrence prediction model, and evaluate patients' recurrence risk after surgery. Relapse-free survival was defined as the time between a patient's initial surgery and the reappearance of evidence of recurrence.

[0042] 1. Materials and methods

[0043] 1. Instruments and equipment

[0044] Real-time PCR System Mx3005p, Agilent, USA

[0045] 2. Real-time PCR reagents

[0046] SYBR Premix Ex Taq TM Takara, Japan

[0047] 3. Real-time PCR primer sequence

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an OLC1 gene expression level in prognosis evaluation of bladder cancer. The invention provides an application of an OLC1 gene as a marker in any one of the following applications: (A1) an application in preparation of a product for prognosis risk assessment of a bladder cancer patient; (A2) application in prognosis risk assessment of bladder cancer patients. The recurrence prediction model constructed by the embodiment of the invention can better predict the prognosis of the bladder urothelial carcinoma patient, and has the potential of clinical application.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of OLC1 gene expression level in bladder cancer prognosis assessment. Background technique [0002] The high recurrence rate of bladder urothelial carcinoma brings heavy economic burden to patients. Bladder cancer can be divided into non-muscle-invasive bladder cancer (tumor stage T0, T1) and muscle-invasive bladder cancer (tumor stage T2, T3, T4) according to whether the tumor invades the muscularis propria. Patients with non-muscle-invasive bladder cancer routinely undergo bladder perfusion and regular cystoscopy after surgery, but the recurrence rate of patients is still as high as 40%-80%. About 50% of patients with muscle-invasive bladder cancer will develop distant metastasis despite radical surgery and lymph node dissection. Although histopathological staging has improved the clinical management of bladder urothelial carcinoma, individualized prog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/11G16B25/20G16B40/00G16H50/30
CPCC12Q1/6886G16B25/20G16B40/00G16H50/30C12Q2600/118C12Q2600/158
Inventor 陈皇蔡曌寿建忠高燕宁
Owner CHINA JAPAN FRIENDSHIP HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com